No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HALO240621P50000
- 0.25
- -0.05-16.67%
15min DelayClose Jun 20 16:00 ET
0.25High0.25Low
0.25Open0.30Pre Close1 Volume211 Open Interest50.00Strike Price25.00Turnover50.55%IV2.18%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.2718Delta0.2246Gamma203.44Leverage Ratio-0.2289Theta-0.0004Rho-55.30Eff Leverage0.0097Vega
Intraday
- 5D
- Daily
News
Halozyme Therapeutics(HALO.US) Officer Sells US$494.26K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 10,000 shares of common stock on Jun 18, 2024 at an average price of $49.426 for a total value of $494.26K.Source: Announcement What is
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $59
TD Cowen analyst Brendan Smith maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 27.3% a
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 494.26K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 18, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Jun 18, with a total market value of approximately $494.26
Don't Ignore The Insider Selling In Halozyme Therapeutics
We wouldn't blame Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders if they were a little worried about the fact that Matthew Posard, the Independent Director recently netted about US$1.0m sellin
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics(HALO.US) Director Sells US$1.01 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Director Posard Matthew L. sold 20,000 shares of common stock on Jun 11, 12, 2024 at an average price of $50.315 for a total value of $1.01 million.Source: Announcemen
Comments
Clinical Updates💉
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
4
EPS growth outshines yearly share price gain, hinting at cautious market sentiment. Despite recent sell-off, long-term investors see 16% annual return over five years, suggesting sell-off may be an opportunity for those seeking long-term growth.
The insider stock selling at Halozyme Therapeutics could raise concerns among shareholders. However, the fact that insiders maintain a considerable amount of shares might suggest some level of alignment between management and smaller shareholders.
Confidence in Halozyme Therapeutics is suggested due to solid EPS growth and significant insider investment aligning with shareholders' interests.
Gapping up
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
11
Read more